Our data suggest that β1EC2-CPs (alone or combined with a β1-receptor blocking drug) might evolve into a novel save and efficient strategy to neutralise stimulating anti-β1EC2 also in human HF. This evidence concerns the gene CAD and hydrops fetalis.